首页> 外文期刊>Lupus >'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010.
【24h】

'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010.

机译:“标准” aPL测试:2010年4月在德克萨斯州加尔维斯顿市举行的第13届国际抗磷脂抗体大会上一个工作组和会前研讨会的报告。

获取原文
获取原文并翻译 | 示例
           

摘要

Current classification criteria for definite antiphospholipid syndrome (APS) mandate the use of one or more of three positive 'standardized' laboratory assays to detect antiphospholipid antibodies (aPL) (viz: anticardiolipin [aCL] IgG and IgM; anti-beta(2)glycoprotein I [anti-beta(2)GPI] antibodies IgG and IgM; and/or a lupus anticoagulant [LAC]), when at least one of the two major clinical manifestations (thrombosis or pregnancy losses) are present. Although, efforts of standardization for these 'criteria' aPL tests have been conducted over the last 27 years, reports of inconsistencies, inter-assay and inter-laboratory variation in the results of aCL, LAC, and anti-beta(2)GPI, and problems with the interpretation and the clinical value of the tests still exist, which affect the consistency of the diagnosis of APS. A Task Force of scientists and pioneers in the field from different countries, subdivided in three working groups, discussed and analyzed critical questions related to 'criteria' aPL tests in an evidence-based manner, during the 13(th) International Congress on Antiphospholipid Antibodies (APLA 2010, April 13-16, 2010, Galveston, TX). These included: review of the standardization and the need for international consensus protocol for aCL and anti-beta(2)GPI tests; the use of monoclonal and/or polyclonal standards in the calibration curve of those tests; and the need for establishment of international units of measurement for anti-beta(2)GPI tests. The group also reviewed the recently updated guidelines for LAC testing, and analyzed and discussed the possibility of stratification of 'criteria' aPL tests as risk factors for APS, as well as the clinical value of single positive vs. multiple aPL positivity. The group members presented, discussed, analyzed data, updated and re-defined those critical questions at a preconference workshop that was open to congress attendees. This report summarizes the findings, conclusions, and recommendations of this Task Force.
机译:明确的抗磷脂综合症(APS)的当前分类标准要求使用三种阳性的“标准化”实验室测定中的一种或多种来检测抗磷脂抗体(aPL)(即:抗心磷脂[aCL] IgG和IgM;抗β(2)糖蛋白当存在两种主要临床表现(血栓形成或妊娠流产)中的至少一种时,我会使用[抗β(2)GPI]抗体IgG和IgM;和/或狼疮抗凝剂[LAC]。尽管在过去的27年中已经为这些“标准” aPL测试进行了标准化工作,但有关aCL,LAC和anti-beta(2)GPI结果不一致,检测间和实验室间差异的报道,仍然存在测试解释和临床价值方面的问题,影响了APS诊断的一致性。在第十三届国际抗磷脂抗体大会上,来自不同国家的科学家和先驱组成的工作队分为三个工作组,以循证方式讨论和分析了与“标准” aPL测试有关的关键问题。 (APLA 2010,2010年4月13日至16日,德克萨斯州加尔维斯顿)。其中包括:审查aCL和抗beta(2)GPI测试的标准化以及对国际共识协议的需求;在这些测试的校准曲线中使用单克隆和/或多克隆标准品;以及需要建立抗β(2)GPI测试的国际度量单位。该小组还审查了最近更新的LAC检测指南,并分析和讨论了将“标准” aPL检测作为APS危险因素进行分层的可能性,以及单项阳性与多项aPL阳性的临床价值。小组成员在向国会参会者开放的会前研讨会上介绍,讨论,分析数据,更新和重新定义这些关键问题。本报告总结了该工作组的发现,结论和建议。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号